$0.7309
-0.05-6.08%
At close: -
$0.7309
0.000.00%
After Hours: Jun 27, 4:34 PM EDT
Comments
Loading...
Ironwood Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IRWD | Benzinga
Ironwood Pharmaceuticals Inc has a consensus price target of $10.09 based on the ratings of 8 analysts. The high is $22 issued by JMP Securities on September 28, 2023. The low is $0.7 issued by Jefferies on April 15, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Jefferies, and Leerink Partners on April 15, 2025, April 15, 2025, and April 14, 2025, respectively. With an average price target of $0.9 between Wells Fargo, Jefferies, and Leerink Partners, there's an implied 23.14% upside for Ironwood Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Jefferies
Leerink Partners
JMP Securities
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Ironwood Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | 36.82% | Wells Fargo | Mohit Bansal67% | $7 → $1 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/15/2025 | Buy Now | -4.23% | Jefferies | Amy Li2% | $8 → $0.7 | Downgrade | Buy → Hold | Get Alert |
| 04/14/2025 | Buy Now | 36.82% | Leerink Partners | Faisal Khurshid37% | $3 → $1 | Maintains | Market Perform | Get Alert |
| 01/30/2025 | Buy Now | 1815.45% | JMP Securities | Roy Buchanan46% | $23 → $14 | Maintains | Market Outperform | Get Alert |
| 01/22/2025 | Buy Now | 994.54% | Craig-Hallum | Chase Knickerbocker56% | $10 → $8 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 584.09% | Leerink Partners | Faisal Khurshid37% | → $5 | Initiates | → Market Perform | Get Alert |
| 08/09/2024 | Buy Now | 1541.81% | Wells Fargo | Mohit Bansal67% | $14 → $12 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 1268.18% | Craig-Hallum | Chase Knickerbocker56% | $14 → $10 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 1815.45% | Craig-Hallum | Chase Knickerbocker56% | $18 → $14 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 1815.45% | Wells Fargo | Mohit Bansal67% | $20 → $14 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 2773.17% | Piper Sandler | David Amsellem74% | $20 → $21 | Maintains | Overweight | Get Alert |
| 01/17/2024 | Buy Now | 2773.17% | Craig-Hallum | Chase Knickerbocker56% | → $21 | Initiates | → Buy | Get Alert |
| 12/14/2023 | Buy Now | 2636.35% | Wells Fargo | Mohit Bansal67% | → $20 | Initiates | → Overweight | Get Alert |
| 09/28/2023 | Buy Now | 2909.99% | JMP Securities | Jason Butler52% | → $22 | Initiates | → Market Outperform | Get Alert |
| 05/23/2023 | Buy Now | 2499.53% | Piper Sandler | David Amsellem74% | $16 → $19 | Maintains | Overweight | Get Alert |
| 08/16/2022 | Buy Now | 1678.63% | Wells Fargo | Jacob Hughes41% | $12 → $13 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Ironwood Pharmaceuticals (IRWD) stock?
The latest price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) was reported by Wells Fargo on April 15, 2025. The analyst firm set a price target for $1.00 expecting IRWD to rise to within 12 months (a possible 36.82% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ironwood Pharmaceuticals (IRWD)?
The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ:IRWD) was provided by Wells Fargo, and Ironwood Pharmaceuticals downgraded their equal-weight rating.
When was the last upgrade for Ironwood Pharmaceuticals (IRWD)?
There is no last upgrade for Ironwood Pharmaceuticals
When was the last downgrade for Ironwood Pharmaceuticals (IRWD)?
The last downgrade for Ironwood Pharmaceuticals Inc happened on April 15, 2025 when Wells Fargo changed their price target from $7 to $1 for Ironwood Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ironwood Pharmaceuticals (IRWD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating Ironwood Pharmaceuticals (IRWD) correct?
While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a downgraded with a price target of $7.00 to $1.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $0.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
